Abstract: |
Impaired transport of methotrexate (MTX) is a common resistance mechanism of tumor cells to this drug. Trimetrexate (TMTX), a second-generation folate antagonist, is still active against MTX-transport-resistant cells because it enters cells by passive diffusion and does not use the reduced folate transport system for cell entry. Therefore, although leucovorin (LV) protects MTX-sensitive cells from TMTX toxicity, MTX-transport defective cells are poorly rescued by LV. Severe combined immunodeficiency mice bearing MTX- transport-resistant CCRF-CEM acute lymphoblastic leukemia tumors were treated with TMTX alone or with the combination of TMTX and LV, with tumor regressions in both groups (P < .001) and without significant toxicity. These results indicate that TMTX with LV protection may be a useful therapeutic regimen for patients with MTX-transport-defective acute lymphoblastic leukemia. Furthermore, resistance to TMTX plus LV may result in reversion to MTX sensitivity. |
Keywords: |
human cell; nonhuman; methotrexate; animal cell; mouse; animal; mice; antineoplastic combined chemotherapy protocols; cytotoxicity; drug effect; drug resistance; mice, scid; acute lymphoblastic leukemia; folinic acid; leukemia cell; transplantation, heterologous; neoplasm transplantation; tumor growth; leucovorin; combined immunodeficiency; biological transport; tumor resistance; cell membrane transport; trimetrexate; protection; leukemia, lymphocytic, acute; active transport; human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|